Evidence map›Paper›PMID 42265993›Full record

Observational studyDeutsches Arzteblatt international2026

Polypharmacy Among 200 000 Subjects of the Population-Based German National Cohort Study (NAKO), Aged 19-74: A Baseline Analysis.

Jonas Peltner, Miriam Degen, Tom Berger, Nina Ebert, Beate Fischer, Kathrin Guenther, Manuela Harries, Volker Harth, Ulrike Haug, Margit Heier and 23 more

Abstract readObservational Study
In one paragraph

Observational study in Deutsches Arzteblatt international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Jonas PeltnerGerman Center for Neurodegenerative Disease (DZNE), Bonn, and Research Division, Federal Institute for Drugs and Medical Devices, Bonn
Miriam DegenClinical Epidemiology of Early Cancer Detection, German Cancer Research Center (DKFZ), Heidelberg, and Medical Faculty, University of Heidelberg
Tom BergerInstitute of Epidemiology and Social Medicine, University of Münster
Nina EbertInstitute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf
Beate FischerDepartment of Epidemiology and Preventive Medicine, University of Regensburg
Kathrin GuentherLeibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen
Manuela HarriesDepartment of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig
Volker HarthInstitute for Occupational and Maritime Medicine (ZfAM), University Medical Centre Hamburg-Eppendorf (UKE)
Ulrike HaugLeibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen
Margit HeierKORA Study Centre, University Hospital Augsburg
André KarchInstitute of Epidemiology and Social Medicine, University of Münster
Verena KatzkeDivision of Cancer Epidemiology (C020), German Cancer Research Center (DKFZ), Heidelberg
Thomas KeilInstitute of Clinical Epidemiology and Biometrics, University of Würzburg, and State Health Institute I, Bavarian State Office for Health and Food Safety, Erlangen
Jasmin KiekertInstitute of Epidemiology and Prevention, University Medical Center Freiburg
Lilian KristInstitute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin
Berit LangeDepartment of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig
Michael LeitzmannDepartment of Epidemiology and Preventive Medicine, University of Regensburg
Jakob LinseisenInstitute of Epidemiology, Medical Faculty, University of Augsburg
Claudia Meinke-FranzeInstitute for Community Medicine, University Medicine Greifswald
Rafael MikolajczykInstitute for Medical Epidemiology, Biometrics, and Informatics, Medical Faculty of the Martin Luther University Halle-Wittenberg
Ilais Moreno VelásquezMax Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin
Nadia ObiInstitute for Occupational and Maritime Medicine (ZfAM), University Medical Centre Hamburg-Eppendorf (UKE)
Phil PendtInstitute for Community Medicine, University Medicine Greifswald
Anette PetersInstitute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Neuherberg
Tobias PischonMax Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin
Thomas ReinholdInstitute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin
Oliver RiedelLeibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen
Börge SchmidtInstitute for Medical Informatics, Biometry and Epidemiology, University Hospital of Essen, University of Duisburg-Essen
Ben SchöttkerClinical Epidemiology of Early Cancer Detection, German Cancer Research Center (DKFZ), Heidelberg
Stefan WillichInstitute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin
Kerstin WirknerInstitute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, and Leipzig Research Centre for Civilization Diseases, University of Leipzig
Matthias WuttkeInstitute for Epidemiology and Prevention, University Hospital Freiburg
Britta HaenischGerman Center for Neurodegenerative Disease (DZNE), Bonn, and Research Division, Federal Institute for Drugs and Medical Devices, Bonn

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPolypharmacy is associated with adverse events, reduced quality of life, and increased mortality, but populationbased studies including both prescribed and over-the-counter medications are scarce.

methodsWe analyzed baseline data from the German National Cohort (NAKO), Germany’s largest population-based cohort study (recruitment 2014–2019; participants aged 19–74 years at baseline). We estimated the proportion of participants with polypharmacy (defined as reporting regular use of ≥ 5 prescribed and over-the-counter medications) and hyperpolypharmacy (≥ 10 medications), stratified by sex and age. Determinants of polypharmacy were estimated using logistic regression.

resultsAmong 203 765 participants (mean age 49.8 years, 50.4% female), 6869 women (6.7%; 95% confidence interval [6.5; 6.8]) and 8126 men (8.0% [7.9; 8.2] reported regular use of ≥ 5 medications. Regular use of ≥ 10 medications was reported by 505 women (0.5% [0.45; 0.54]) and 722 men (0.7% [0.67;0.77]). Polypharmacy and hyperpolypharmacy increased with age. Diabetes and chronic cardiovascular conditions were strong determinants. Use of cardiovascular medications was most frequently reported.

conclusionPolypharmacy was common in NAKO, particularly among older participants, men, and persons with cardiovascular disease. Because medication appropriateness could not be assessed, future studies should examine inappropriate polypharmacy and evaluate risk factors and strategies for deprescribing.

Indexed as

PolypharmacyAdultAgedCohort StudiesFemaleGermanyHumansMaleMiddle AgedYoung Adult

Identifiers

PMID42265993
PMCPMC13588097

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.